Abstract
London health sciences center is a frequent user of Lu-177
Dotatate for the treatment of #neuroendocrinedisease. We began
using this #radionuclidetherapy as an in-patient procedure, where
patients were released at 20 hours’ post therapy administration
with minimal restrictions. Over the course of 2013, we worked
to transform this therapy into an outpatient procedure, where
patients were released at 4-6 hours’ post therapy administration
with major restrictions. The previous methods and data we
presented in December 17, 2013 were based on dose rates derived
from cumulated doses measured over approximately 16 hours, and
an assumption of Lu-177 clearance based on radioactive decay
only. Since 2013, our hospital has gained more experience with
Lu-177 Dotatate, enabling us to develop a better understanding
of #dosimetry. We describe new dose measurements, a new model
we developed to describe our observations, and a revised schedule
of patient release and restriction duration. Compared against
previous measurements from 2013, our new measurements are of
instantaneous (not cumulative) dose rates, and we now consider
Lu-177 clearance to proceed both by physical decay and biologic
excretion. Our new proposed model combines our experimental
results with results from literature. The model will state the dose
rate from time of discharge can be modeled as a decaying double
exponential function [1-5].
For more biomedical open access journals please click on
Experimental Results for Outpatient #treatment with Lu-177 Dotatate External #Dosimetry by Mushref Algarni in BJSTR
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.